Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Boomskidon May 04, 2023 1:39pm
117 Views
Post# 35430561

If Prothena's PRX012 is an xB3 drug, then...

If Prothena's PRX012 is an xB3 drug, then...
It's true that Prothena's PRX012 could have been modified with xB3 before IND submissions, etc., and it could have been done without disclosure by either Prothena or Bioasis. 
 
If xB3 is a part of PRX012, and if Rathjen is allowing Bioasis to fail without revealing that xB3 is working as hoped, then Bioasis shareholders are watching Bioasis fail without being adequately informed.
 
That has meaning and LET ME SHOUT IT:
 
IF AN xB3 DRUG IS CURRENTLY IN CLINICAL TRIALS AND BIOASIS WAS BEING SOLD TO MIDATECH WITHOUT SHAREHOLDERS KNOWING THAT xB3 WORKS AS HOPED, THEN BIOASIS  SHAREHOLDERS ARE BEING TREATED IN A MANNER THAT SOME MAY CONSIDER TO BEING SWINDLED.
 
FURTHER, IF AN xB3 DRUG IS IN CLINICAL TRIALS AND THAT IS NOT BEING REPORTED, THEN THE MARKET IS VALUING BIOASIS AS A FAILURE AT 1 CENT WITHOUT INVESTORS HAVING ENOUGH INFORMATION TO PROPERLY EVALUATE THE COMPANY.
 
If that's not BREAKING THE RULES then I'd like to know what it is.
 
So, what kind of bet on BTI should be made if it is suspected that PRX012 is an xB3 drug? Should we be buying BTI at these prices? Were Ladenburg Thalmann and their clients aware of xB3 success about which Bioasis shareholders had no knowledge?
 
If this Prothena thing is true, then what kind of CEO would keep that secret? Why couldn't the CEO make a statement? She could communicate something like the following:
 
"Bioasis announced today that an xB3 drug has shown significant preliminary success and is now in human clinical trials. The type and nature of the drug, its target disorder, and the drug's owner cannot be revealed under the terms of the licensing agreement between Bioasis and the company that is advancing the drug. Bioasis is very encouraged by the success that xB3 is showing, etc., etc."

Sooner or later, Bioasis would have to make a similar statement about some other company 

So, is xB3 actually working? If PRX012 is an xB3 drug and if it works, then what should the Bioasis share price be? What about the "shelved" xB3-001?

Is Bioasis really worth only 1 cent?

It's time to light this candle!

jd
 
<< Previous
Bullboard Posts
Next >>